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A recent editorial in Travel Medicine and Infectious Diseases highlighted the lack of studies 
about Zika virus (ZIKV) in pregnancy and its implications in many countries [1]. Zika virus 
infection can induce congenital defects in the newborn such as microcephaly and miscarriage 
when mothers are infected during pregnancy [2]. However, relevant questions remain to be 
completely understood, such as the risk of infection for pregnant women and of subsequent 
congenital defects, and the ratio between symptomatic and asymptomatic ZIKV infections in 
the general population and in pregnant women. Here, we describe the results of a ZIKV 
screening of pregnant women in Catalonia, northeastern Spain. Testing for ZIKV was 
recommended for all pregnant women with history of travel to ZIKV endemic areas during 
pregnancy or in the 8 weeks before conception [3]. Symptomatic patients were screened by 
serological methods from day four after the onset of symptoms and by molecular methods 
within the first week (serum) and two weeks (urine) after illness. Asymptomatic patients were 
tested by serological methods. Seroneutralization assay for ZIKV was perfomed in samples 
positive for antibodies. Commercial diagnostic assays were used (RT-PCR, Altona Diagnostics 
and IIFT, Euroimmun). Neutralization titers ≥ 1/32 were considered indicative of the presence 
of ZIKV neutralizing antibodies. Follow up at two designated reference obstetrical departments 
for early detection of microcephaly or other malformations was offered to pregnant women 
with laboratory evidence of ZIKV infection. When available, amniotic fluid and placental tissue 
samples were tested for ZIKV by RT-PCR in cases of microcephaly or miscarriage, respectively. 
A ZIKV confirmed case was defined as i) a pregnant woman with a positive RT-PCR test for ZIKV 
in serum and/or urine samples and/or ii) a pregnant woman with a positive IgM against ZIKV, a 
negative IgM against dengue virus and a ZIKV neutralization titer ≥ 1/32. A ZIKV probable case 
was defined as a pregnant woman with an isolated positive IgG test against ZIKV and a ZIKV 
neutralization titer ≥1/32. All cases with no laboratory evidence of ZIKV infection and cases 
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with an isolated positive IgG test and a ZIKV neutralization titer <1/32 were considered 
negative cases.  
A total of 1057 pregnant women with history of potential exposure to ZIKV were tested 
between January and December 2016. The results of the screening, clinical presentation and 
pregnancy outcomes are summarized in Figure 1.  
 
Figure 1. Screening results, clinical presentation and adverse pregnancy outcomes of 1057 
pregnant women screened for ZIKV infection.  



























The median age of the pregnant women undergoing ZIKV screening was 31 years (range 15-
49). The country most frequently visited was the Dominican Republic (113 women; 14.2%) 
followed by Bolivia (97, 12.2%), Ecuador (90; 11.3%) and Colombia (88; 11.0%). Information 
about the gestational age in which the women were potentially exposed to ZIKV was available 
in 683/1057 women (62.8%). Thirty-five (5.1%) stayed in ZIKV endemic areas within one month 
before conception, 482 (70.6%) during the first trimester, 117 (17.1%) during the second 
trimester and 49 (7.2%) during the third trimester. Clinical information was available in 946 
patients (89.5%) and most of them (846; 89.4%) had not presented ZIKV compatible 
symptoms. Overall, ZIKV infection was confirmed in 14 out of the 1057 potentially exposed 
pregnant women (1.3%; 95%CI: 0.7-2.2%) and this figure rose to 142/1057 (13.4%; 95%CI: 
11.4%-15.6%) considering women with any laboratory evidence of ZIKV infection (confirmed 
and probable cases). Of the 14 confirmed ZIKV cases, 12 were diagnosed by RT-PCR and two by 
serological methods.   
We detected three adverse fetal outcomes associated with ZIKV infection: one newborn with 
microcephaly and two miscarriages. In the case with microcephaly, ZIKV RNA was detected in 
amniotic fluid [4]. In both cases of miscarriage, ZIKV RNA was detected in placental tissues and 
in one case ZIKV was, in addition, isolated from embryonic cells [5]. In forty-six probable cases, 
the information on the final pregnancy outcome was not available, but no fetal abnormalities 
were found at the time of screening. Our data show a prevalence of serious adverse effects 
(microcephaly or miscarriage) associated with ZIKV infection of 3/96 (3.1%; 95% CI:0.6%-8.9%) 
among pregnant women with laboratory evidence of ZIKV infection. Importantly, in the three 
cases, ZIKV infection occurred in the first trimester of pregnancy. Moreover, the three cases 
were symptomatic and laboratory confirmed.  
ZIKV infection in pregnancy, particularly during the first trimester in which the central nervous 
system of the fetus is being formed, is associated with adverse fetal outcomes such us 
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miscarriage and microcephaly among others [2]. There is a lack of published data from cohorts 
of pregnant women residing in Europe and who have been potentially exposed to ZIKV during 
pregnancy. A recent systematic review and metaanalysis based on series from the Americas 
estimated the prevalence of microcephaly of 2.3% [95%CI: 1.0%–5.3%] among babies born to 
ZIKV-infected mothers [6]. Our results from pregnant women with any laboratory evidence of 
ZIKV infection are in concordance with these figures. Among eight published studies, the 
proportion of asymptomatic ZIKV infections in pregnant women ranged from 17.2 to 56% [6]. 
Our study revealed that among women with any laboratory evidence of ZIKV infection only 
25% presented symptoms. However, 85.7% (12 out of 14) laboratory confirmed ZIKV cases 
were symptomatic. These differences may be explained considering that ZIKV symptomatic 
patients may be more likely to seek medical attention and therefore might be more likely to be 
laboratory confirmed by RT-PCR in the acute phase of the illness. In contrast, asymptomatic 
cases are mainly detected by serology and therefore are more likely to be classified as 
probable cases.  
Our study has several limitations. Firstly, the high cross reactivity between dengue and ZIKV 
induced antibodies and the absence of available neutralization tests against DENV in our 
setting hampered a more precise classification of the group of probable ZIKV infections. 
Secondly, other relevant risk factors such as precise duration of the trip or stay in the endemic 
areas, magnitude of the ZIKV circulation in each country at the time of visit and use of 
repellents or other measures against mosquito bites, were not systematically assessed. 
Despite these limitations, some of them being certainly difficult to address, we present the 
screening results from more than 1000 pregnant women who were screened for ZIKV 
infection. Our results contribute to better understand the impact of ZIKV infection in 
pregnancy and might be helpful to estimate the risk of poor pregnancy outcomes for pregnant 
women living in Europe who travel to ZIKV affected areas, as well as to evaluate the 
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